Test different doses of cancer drugs with ezabenlimab
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that cannot be removed by surgery, or it has spread, and it has been confirmed by a biopsy or scan test
- Your cancer must have at least one measurable spot the trial can track, and you must be able to provide two tumor biopsies (before treatment and during treatment)
- You are age 18 or older, and you sign informed consent (you can still join without agreeing to extra optional tissue storage/biobanking)
- Your body health/lab tests must be strong enough (blood counts, kidney function, liver tests) for safe study treatment
- You should be well enough to do daily activities (ECOG score 0 or 1)
- You must not have had certain recent cancer treatments, some prior immune drug exposures, or immune-related lung problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
This study tests a new investigational drug called BI 3968621, given either by itself or with another drug called ezabenlimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe and effective doses and see if the combination helps shrink tumors or slow their growth.
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.